Citius Oncology, Inc. (CTOR) Stock Competitors & Peer Comparison
See (CTOR) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CTOR | $0.72 | -10.01% | 64.6M | -1.45 | -$0.48 | N/A |
| LLY | $1,144.03 | -0.45% | 1.1T | 40.61 | $28.17 | +0.56% |
| JNJ | $237.00 | +2.08% | 570.7B | 27.44 | $8.64 | +2.21% |
| ABBV | $225.42 | +1.05% | 398.2B | 109.93 | $2.05 | +2.98% |
| MRK | $119.60 | +0.07% | 295.3B | 33.68 | $3.55 | +2.76% |
| NVS | $149.12 | +1.84% | 284.5B | 21.36 | $6.98 | +3.17% |
| AZN | $183.43 | +1.04% | 284.4B | 27.61 | $6.64 | +1.74% |
| AMGN | $344.57 | -0.34% | 186B | 23.98 | $14.37 | +2.85% |
| GILD | $125.50 | -2.03% | 155.8B | 14.99 | $8.37 | +2.54% |
| PFE | $25.70 | +0.31% | 146.3B | 19.60 | $1.31 | +6.68% |
Stock Comparison
CTOR vs LLY Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, CTOR is priced at $0.72, while LLY trades at $1,144.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas LLY's P/E ratio is 40.61. In terms of profitability, CTOR's ROE is -0.99%, compared to LLY's ROE of +1.01%. Regarding short-term risk, CTOR is more volatile compared to LLY. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.Check LLY's competition here
CTOR vs JNJ Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, JNJ has a market cap of 570.7B. Regarding current trading prices, CTOR is priced at $0.72, while JNJ trades at $237.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas JNJ's P/E ratio is 27.44. In terms of profitability, CTOR's ROE is -0.99%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, CTOR is more volatile compared to JNJ. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.Check JNJ's competition here
CTOR vs ABBV Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, ABBV has a market cap of 398.2B. Regarding current trading prices, CTOR is priced at $0.72, while ABBV trades at $225.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas ABBV's P/E ratio is 109.93. In terms of profitability, CTOR's ROE is -0.99%, compared to ABBV's ROE of +0.68%. Regarding short-term risk, CTOR is more volatile compared to ABBV. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.Check ABBV's competition here
CTOR vs MRK Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, MRK has a market cap of 295.3B. Regarding current trading prices, CTOR is priced at $0.72, while MRK trades at $119.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas MRK's P/E ratio is 33.68. In terms of profitability, CTOR's ROE is -0.99%, compared to MRK's ROE of +0.18%. Regarding short-term risk, CTOR is more volatile compared to MRK. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.Check MRK's competition here
CTOR vs NVS Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, NVS has a market cap of 284.5B. Regarding current trading prices, CTOR is priced at $0.72, while NVS trades at $149.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas NVS's P/E ratio is 21.36. In terms of profitability, CTOR's ROE is -0.99%, compared to NVS's ROE of +0.32%. Regarding short-term risk, CTOR is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.Check NVS's competition here
CTOR vs AZN Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, AZN has a market cap of 284.4B. Regarding current trading prices, CTOR is priced at $0.72, while AZN trades at $183.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas AZN's P/E ratio is 27.61. In terms of profitability, CTOR's ROE is -0.99%, compared to AZN's ROE of +0.22%. Regarding short-term risk, CTOR is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.Check AZN's competition here
CTOR vs AMGN Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, AMGN has a market cap of 186B. Regarding current trading prices, CTOR is priced at $0.72, while AMGN trades at $344.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas AMGN's P/E ratio is 23.98. In terms of profitability, CTOR's ROE is -0.99%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, CTOR is more volatile compared to AMGN. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.Check AMGN's competition here
CTOR vs GILD Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, GILD has a market cap of 155.8B. Regarding current trading prices, CTOR is priced at $0.72, while GILD trades at $125.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas GILD's P/E ratio is 14.99. In terms of profitability, CTOR's ROE is -0.99%, compared to GILD's ROE of +0.42%. Regarding short-term risk, CTOR is more volatile compared to GILD. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.Check GILD's competition here
CTOR vs PFE Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, PFE has a market cap of 146.3B. Regarding current trading prices, CTOR is priced at $0.72, while PFE trades at $25.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas PFE's P/E ratio is 19.60. In terms of profitability, CTOR's ROE is -0.99%, compared to PFE's ROE of +0.08%. Regarding short-term risk, CTOR is more volatile compared to PFE. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.Check PFE's competition here
CTOR vs BMY Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, BMY has a market cap of 115.3B. Regarding current trading prices, CTOR is priced at $0.72, while BMY trades at $56.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas BMY's P/E ratio is 15.82. In terms of profitability, CTOR's ROE is -0.99%, compared to BMY's ROE of +0.39%. Regarding short-term risk, CTOR is more volatile compared to BMY. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.Check BMY's competition here
CTOR vs SNY Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, SNY has a market cap of 107.7B. Regarding current trading prices, CTOR is priced at $0.72, while SNY trades at $44.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas SNY's P/E ratio is 19.45. In terms of profitability, CTOR's ROE is -0.99%, compared to SNY's ROE of +0.11%. Regarding short-term risk, CTOR is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.Check SNY's competition here
CTOR vs GSK Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, GSK has a market cap of 103B. Regarding current trading prices, CTOR is priced at $0.72, while GSK trades at $51.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas GSK's P/E ratio is 13.52. In terms of profitability, CTOR's ROE is -0.99%, compared to GSK's ROE of +0.28%. Regarding short-term risk, CTOR is more volatile compared to GSK. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.Check GSK's competition here
CTOR vs ZTS Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, ZTS has a market cap of 34.4B. Regarding current trading prices, CTOR is priced at $0.72, while ZTS trades at $82.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas ZTS's P/E ratio is 13.46. In terms of profitability, CTOR's ROE is -0.99%, compared to ZTS's ROE of +0.62%. Regarding short-term risk, CTOR is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.Check ZTS's competition here
CTOR vs BIIB Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, BIIB has a market cap of 29.4B. Regarding current trading prices, CTOR is priced at $0.72, while BIIB trades at $199.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas BIIB's P/E ratio is 21.41. In terms of profitability, CTOR's ROE is -0.99%, compared to BIIB's ROE of +0.08%. Regarding short-term risk, CTOR is more volatile compared to BIIB. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.Check BIIB's competition here
CTOR vs HZNP Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, CTOR is priced at $0.72, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas HZNP's P/E ratio is 61.86. In terms of profitability, CTOR's ROE is -0.99%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, CTOR is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.Check HZNP's competition here
CTOR vs GRFS Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, GRFS has a market cap of 6.2B. Regarding current trading prices, CTOR is priced at $0.72, while GRFS trades at $7.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas GRFS's P/E ratio is 10.34. In terms of profitability, CTOR's ROE is -0.99%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, CTOR is more volatile compared to GRFS. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.Check GRFS's competition here
CTOR vs OGN Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, OGN has a market cap of 3.5B. Regarding current trading prices, CTOR is priced at $0.72, while OGN trades at $13.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas OGN's P/E ratio is 14.41. In terms of profitability, CTOR's ROE is -0.99%, compared to OGN's ROE of +0.30%. Regarding short-term risk, CTOR is more volatile compared to OGN. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.Check OGN's competition here
CTOR vs CELG-RI Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, CELG-RI has a market cap of 219.5M. Regarding current trading prices, CTOR is priced at $0.72, while CELG-RI trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -0.99%, compared to CELG-RI's ROE of +0.39%. Regarding short-term risk, CTOR is more volatile compared to CELG-RI. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.Check CELG-RI's competition here
CTOR vs SCLX Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, SCLX has a market cap of 59.8M. Regarding current trading prices, CTOR is priced at $0.72, while SCLX trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas SCLX's P/E ratio is -0.17. In terms of profitability, CTOR's ROE is -0.99%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, CTOR is more volatile compared to SCLX. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.Check SCLX's competition here
CTOR vs MIRA Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, MIRA has a market cap of 41M. Regarding current trading prices, CTOR is priced at $0.72, while MIRA trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas MIRA's P/E ratio is -0.77. In terms of profitability, CTOR's ROE is -0.99%, compared to MIRA's ROE of -1.41%. Regarding short-term risk, CTOR is more volatile compared to MIRA. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.Check MIRA's competition here
CTOR vs SRXH Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, SRXH has a market cap of 4.1M. Regarding current trading prices, CTOR is priced at $0.72, while SRXH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas SRXH's P/E ratio is -0.71. In terms of profitability, CTOR's ROE is -0.99%, compared to SRXH's ROE of +8.75%. Regarding short-term risk, CTOR is more volatile compared to SRXH. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.Check SRXH's competition here
CTOR vs SCLXW Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, SCLXW has a market cap of 1.4M. Regarding current trading prices, CTOR is priced at $0.72, while SCLXW trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas SCLXW's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -0.99%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, CTOR is more volatile compared to SCLXW. This indicates potentially higher risk in terms of short-term price fluctuations for CTOR.Check SCLXW's competition here
CTOR vs BDSIW Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, CTOR is priced at $0.72, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas BDSIW's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -0.99%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, CTOR is less volatile compared to BDSIW. This indicates potentially lower risk in terms of short-term price fluctuations for CTOR.Check BDSIW's competition here
CTOR vs CRXT Comparison June 2026
CTOR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTOR stands at 64.6M. In comparison, CRXT has a market cap of 0. Regarding current trading prices, CTOR is priced at $0.72, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTOR currently has a P/E ratio of -1.45, whereas CRXT's P/E ratio is -0.02. In terms of profitability, CTOR's ROE is -0.99%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, CTOR is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for CTOR.Check CRXT's competition here